Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ISAAC TAFUR

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1679536387
CMS profile
30754
Location
LUBBOCK, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$96.84

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $83.58 5
Food and Beverage $13.26 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $83.58 5
Genentech USA, Inc. $13.26 1

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ISAAC TAFUR

NPI 1679536387 · CMS profile ID 30754

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

LUBBOCK, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679536387?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ISAAC TAFUR, NPI 1679536387, CMS profile ID 30754. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679536387?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ISAAC TAFUR, NPI 1679536387, CMS profile ID 30754. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679536387?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ISAAC TAFUR, NPI 1679536387, CMS profile ID 30754, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1679536387?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $96.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $13.8610/20/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049565391 CMS
PFIZER INC. $13.8610/11/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049566065 CMS
PFIZER INC. $21.0010/11/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049567423 CMS
Genentech USA, Inc. $13.2609/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040381713 CMS
PFIZER INC. $13.8609/01/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049573663 CMS
PFIZER INC. $21.0009/01/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049575041 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $828.42 56
PY2020 $118.08 9
PY2021 $138.59 9
PY2022 $11.97 1
PY2023 $96.84 6
PY2024 $472.12 20
PY2025 $636.04 26

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $24,700.00 2
PY2024 Principal investigator $850.00 2
PY2023 Principal investigator $16,152.90 11
PY2022 Principal investigator $75,305.83 35
PY2021 Principal investigator $57,088.81 68
PY2020 Principal investigator $164,987.76 78
PY2019 Principal investigator $218,143.35 88

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

78 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Seagen Inc. $300.00 12/23/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 733454649
Principal investigator 1 Seagen Inc. $6,415.41 12/23/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 733454653
Principal investigator 1 PFIZER INC. $2,500.00 12/10/2020 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 742900197
Principal investigator 1 Seagen Inc. $79.31 11/23/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 733454645
Principal investigator 1 Seagen Inc. $2,500.00 11/23/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 733454651
Principal investigator 1 Seagen Inc. $480.00 11/23/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733454673
Principal investigator 1 Seagen Inc. $100.00 11/18/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 733454647
Principal investigator 1 Seagen Inc. $18,034.89 10/23/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733454671
Principal investigator 1 Seagen Inc. $21,898.19 10/20/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 733454655
Principal investigator 1 Seagen Inc. $961.28 10/14/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733454675
Principal investigator 1 Incyte Corporation $2,500.00 09/17/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275191
Principal investigator 1 Incyte Corporation $8,000.00 09/17/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275193
Principal investigator 1 Incyte Corporation $1,600.00 09/17/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275195
Principal investigator 1 Incyte Corporation $945.00 09/17/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275197
Principal investigator 1 Incyte Corporation $2,500.00 09/17/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275199
Principal investigator 1 Incyte Corporation $1,600.00 09/17/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275201
Principal investigator 1 Seagen Inc. $1,000.00 09/10/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 733454609
Principal investigator 1 Seagen Inc. $15,098.19 08/26/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733454623
Principal investigator 1 PFIZER INC. $3,031.26 08/20/2020 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 742911285
Principal investigator 1 Seagen Inc. $800.00 08/04/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 733454607
Principal investigator 1 Seagen Inc. $35.96 08/04/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733454627
Principal investigator 1 Seagen Inc. $2,001.11 07/07/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733454625
Principal investigator 1 Seagen Inc. $2,500.00 07/07/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer (MOUNTAINEER) No dispute reported 06/30/2026 733454629
Principal investigator 1 Seagen Inc. $800.00 07/07/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer (MOUNTAINEER) No dispute reported 06/30/2026 733454631
Principal investigator 1 PFIZER INC. $750.00 07/01/2020 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 742907321
Principal investigator 1 PFIZER INC. $1,802.76 06/16/2020 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 742907711
Principal investigator 1 Seagen Inc. $35.96 06/16/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733454379
Principal investigator 1 Seagen Inc. $2,500.00 06/09/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733454377
Principal investigator 1 Seagen Inc. $12,600.00 06/09/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer (MOUNTAINEER) No dispute reported 06/30/2026 733454399
Principal investigator 1 Eli Lilly and Company $5,687.85 06/02/2020 Non-covered Recipient Entity
METHODIST CHILDRENS HOSPITAL DBA COVENANT CHILDRENS HOSPITAL
A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH NIVOLUMAB VS. NIVOLUMAB ALONE AS SECOND-LINE THERAPY IN SUBJECTS WITH STAGE IV / METASTATIC WILD TYPE NON-SMALL CELL LUNG CANCER AND LOW TUMOR EXPRESSION OF PD-L1 No dispute reported 06/30/2026 728738785
Principal investigator 1 Seagen Inc. $750.00 06/02/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733454375
Principal investigator 1 Seagen Inc. $227.50 05/28/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733454369
Principal investigator 1 PFIZER INC. $500.00 05/19/2020 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 742908497
Principal investigator 1 Seagen Inc. $500.00 05/06/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733454371
Principal investigator 1 Seagen Inc. $2,643.52 05/06/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733454373
Principal investigator 1 PFIZER INC. $6,553.09 05/05/2020 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 742908737
Principal investigator 1 PFIZER INC. $2,960.75 05/05/2020 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 742912353
Principal investigator 1 PFIZER INC. $1,978.18 04/21/2020 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 742906591
Principal investigator 1 PFIZER INC. $1,978.18 04/21/2020 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 742907039
Principal investigator 1 PFIZER INC. $2,603.25 04/21/2020 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 742907175
Principal investigator 1 PFIZER INC. $2,960.75 04/21/2020 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 742909921
Principal investigator 1 PFIZER INC. $4,406.01 04/21/2020 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 742909991
Principal investigator 1 Incyte Corporation $10.80 04/08/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275115
Principal investigator 1 Incyte Corporation $70.21 04/08/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275117
Principal investigator 1 Incyte Corporation $35.80 04/08/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275119
Principal investigator 1 Incyte Corporation $103.60 04/08/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275121
Principal investigator 1 Incyte Corporation $30.09 04/08/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275123
Principal investigator 1 Incyte Corporation $0.02 04/08/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275125
Principal investigator 1 Incyte Corporation $0.10 04/08/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275127
Principal investigator 1 Incyte Corporation $52.12 04/08/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275129
Principal investigator 1 Incyte Corporation $15.40 04/08/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275131
Principal investigator 1 Incyte Corporation $10.80 04/08/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275141
Principal investigator 1 Incyte Corporation $10.80 04/08/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275143
Principal investigator 1 Incyte Corporation $10.80 04/08/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275145
Principal investigator 1 Incyte Corporation $10.80 04/08/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275147
Principal investigator 1 Incyte Corporation $10.80 04/08/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Pemigatinib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment No dispute reported 06/30/2026 744275149
Principal investigator 1 Incyte Corporation $17.90 04/02/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 744275101
Principal investigator 1 Incyte Corporation $35.80 04/02/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 744275103
Principal investigator 1 Incyte Corporation $0.80 04/02/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 744275105
Principal investigator 1 Incyte Corporation $53.70 04/02/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 744275107
Principal investigator 1 Incyte Corporation $10.00 04/02/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 744275109
Principal investigator 1 Incyte Corporation $15.40 04/02/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 744275111
Principal investigator 1 Incyte Corporation $52.12 04/02/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 744275113
Principal investigator 1 Incyte Corporation $17.90 04/02/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 744275133
Principal investigator 1 Incyte Corporation $17.90 04/02/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 744275135
Principal investigator 1 Incyte Corporation $17.90 04/02/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 744275137
Principal investigator 1 Incyte Corporation $35.80 04/02/2020 Covered Recipient Teaching Hospital
Covenant Health System
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement (FIGHT-205) No dispute reported 06/30/2026 744275139
Principal investigator 1 PFIZER INC. $500.00 03/24/2020 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 742911237
Principal investigator 1 Seagen Inc. $500.00 03/11/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 733454363
Principal investigator 1 Eli Lilly and Company $5,403.25 02/19/2020 Non-covered Recipient Entity
METHODIST CHILDRENS HOSPITAL DBA COVENANT CHILDRENS HOSPITAL
A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE HIGH PD-L1 EXPRESSION No dispute reported 06/30/2026 728744777
Principal investigator 1 Exelixis Inc. $202.80 02/06/2020 Non-covered Recipient Entity
Methodist Children's Hospital dba Covenant Children's Hospital
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736575079
Principal investigator 1 Exelixis Inc. $269.43 02/06/2020 Non-covered Recipient Entity
Methodist Children's Hospital dba Covenant Children's Hospital
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736575081
Principal investigator 1 Exelixis Inc. $1,000.00 02/04/2020 Non-covered Recipient Entity
Methodist Children's Hospital dba Covenant Children's Hospital
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736575083
Principal investigator 1 PFIZER INC. $2,500.00 01/21/2020 Covered Recipient Teaching Hospital
COVENANT HEALTH SYSTEM
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLYTAREGISTERED VERSUS SUNITINIB SUTENTREGISTERED MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA No dispute reported 06/30/2026 742906141
Principal investigator 1 Seagen Inc. $316.62 01/21/2020 Non-covered Recipient Entity
JOE ARRINGTON CANCER CENTER
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 733454585
Principal investigator 1 Exelixis Inc. $6,242.60 01/07/2020 Non-covered Recipient Entity
Methodist Children's Hospital dba Covenant Children's Hospital
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736574605
Principal investigator 1 Exelixis Inc. $240.50 01/07/2020 Non-covered Recipient Entity
Methodist Children's Hospital dba Covenant Children's Hospital
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736574607
Principal investigator 1 Exelixis Inc. $46.80 01/07/2020 Non-covered Recipient Entity
Methodist Children's Hospital dba Covenant Children's Hospital
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 736574609